Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

BACKGROUND: Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of limited duration. Conversely, responses to ipilimumab take time to devel...

Full description

Saved in:
Bibliographic Details
Main Authors: Ascierto, Paolo A, Simeone, Ester, Giannarelli, Diana, Grimaldi, Antonio M, Romano, Anna, Mozzillo, Nicola
Format: Artigo
Language:Inglês
Published: BioMed Central 2012
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3464706/
https://ncbi.nlm.nih.gov/pubmed/22640478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-107
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items